{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=XL184", "query": { "intervention": "XL184" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 200, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=XL184&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T16:41:58.472Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05048212", "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05048212" }, { "nct_id": "NCT05327686", "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Ablative Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2023-02-01", "completion_date": "2033-06-15", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 323, "location_summary": "Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327686" }, { "nct_id": "NCT04197310", "title": "Cabozantinib and Nivolumab for Carcinoid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoid Tumor", "Carcinoid Tumor of GI System", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-12-26", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197310" }, { "nct_id": "NCT04868773", "title": "Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Carcinoma", "Metastatic Cancer", "CRC" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 15, "start_date": "2021-07-16", "completion_date": "2024-04-09", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04868773" }, { "nct_id": "NCT01428219", "title": "Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2012-02", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01428219" }, { "nct_id": "NCT04551430", "title": "Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Soft-tissue Sarcoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2021-01-05", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 4, "location_summary": "Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551430" }, { "nct_id": "NCT04353765", "title": "Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Locally Advanced or Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib monotherapy", "type": "DRUG" }, { "name": "All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2020-01-30", "completion_date": "2020-06-05", "has_results": false, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 1, "location_summary": "The Woodlands, Texas", "locations": [ { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04353765" }, { "nct_id": "NCT03370718", "title": "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Carcinoma in the Adrenal Cortex", "Stage III Adrenal Cortex Carcinoma AJCC v8", "Stage IV Adrenal Cortex Carcinoma AJCC v8", "Unresectable Adrenal Cortex Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-02-26", "completion_date": "2024-01-12", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03370718" }, { "nct_id": "NCT03867045", "title": "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Renal Cell Carcinoma Treated With Cabozantinib" ], "interventions": [ { "name": "Usability of an electronic symptom management application", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-08-21", "completion_date": "2019-12-16", "has_results": false, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 2, "location_summary": "Durham, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867045" }, { "nct_id": "NCT05797805", "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tegavivint", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Iterion Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2023-09-13", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-09-05T16:41:58.472Z", "location_count": 7, "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05797805" } ] }